Turan B. Letter to the Editor: Helicobacter pylori eradication in chronic aspirin users - a gastrointestinal strategy with cardiovascular implications? World J Gastroenterol 2026; 32(37): 120403 [DOI: 10.3748/wjg.120403]
Corresponding Author of This Article
Bilal Turan, MD, Assistant Professor, Researcher, Department of General Surgery, Faculty of Medicine, Suleyman Demirel University, Suleyman Demirel Universitesi Arastirma ve Uygulama Hastanesi, Isparta 32260, Türkiye. bturan117@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
letter
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Turan B. Letter to the Editor: Helicobacter pylori eradication in chronic aspirin users - a gastrointestinal strategy with cardiovascular implications? World J Gastroenterol 2026; 32(37): 120403 [DOI: 10.3748/wjg.120403]
World J Gastroenterol. Oct 7, 2026; 32(37): 120403 Published online Oct 7, 2026. doi: 10.3748/wjg.120403
Letter to the Editor: Helicobacter pylori eradication in chronic aspirin users - a gastrointestinal strategy with cardiovascular implications?
Bilal Turan
Bilal Turan, Department of General Surgery, Faculty of Medicine, Suleyman Demirel University, Isparta 32260, Türkiye
Author contributions: Turan B designed the overall concept and outline of the manuscript, contributed to the design and writing of the manuscript, and reviewed the literature.
AI contribution statement: Limited AI-assisted tools were used only for language assistance and translation. The entire scientific content of the manuscript was written by the author. Study design, data analysis, and interpretation were performed entirely by the author.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Bilal Turan, MD, Assistant Professor, Researcher, Department of General Surgery, Faculty of Medicine, Suleyman Demirel University, Suleyman Demirel Universitesi Arastirma ve Uygulama Hastanesi, Isparta 32260, Türkiye. bturan117@gmail.com
Received: February 26, 2026 Revised: April 12, 2026 Accepted: May 12, 2026 Published online: October 7, 2026 Processing time: 187 Days and 22.1 Hours
Core Tip
Core Tip: Persistent Helicobacter pylori (H. pylori) infection in chronic low-dose aspirin users may represent more than a gastrointestinal risk factor. In the prospective cohort study by Semeya et al, persistent infection was associated not only with increased peptic ulcer bleeding but also with short-term cardiovascular (CV) progression, whereas successful eradication was linked to fewer bleeding and CV events. These findings raise the possibility that H. pylori status may function as a modifiable component within an integrated gastrointestinal-CV risk framework. Although causality cannot be established from observational data, the study highlights the potential value of considering H. pylori assessment in selected high-risk aspirin users and emphasizes the need for randomized trials to clarify its CV implications.
